Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 74 of 82 for:    acne AND Acne Scars

Evaluation of Cutera Excel V™ Laser With Green Genesis and Micro-Lens Array (MLA)Attachment

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03424304
Recruitment Status : Active, not recruiting
First Posted : February 7, 2018
Last Update Posted : March 14, 2018
Sponsor:
Information provided by (Responsible Party):
Cutera Inc.

Brief Summary:
Evaluate the Cutera excel V™ Laser with Green Genesis and a Micro-Lens Array (MLA) Attachment

Condition or disease Intervention/treatment Phase
Wrinkle Rosacea Scarring Device: Excel V™ Laser With Green Genesis Not Applicable

Detailed Description:
This is an open-label, prospective, single-center, split-face Feasibility study to Evaluate 1) the safety and efficacy of the Cutera excel V™ laser and the Micro-Lens Array attachment to the Genesis V hand piece, and 2) the safety and efficacy of the Cutera excel V™ laser Green Genesis V hand piece to the CoolView hand piece.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 20 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Other
Official Title: Open-label, Prospective, Single-Center Feasibility Study to Evaluate the Cutera Excel V™ Laser With Green Genesis and a Micro-Lens Array Attachment as Compared to the Standard-of-care With an Excel V™ Laser
Actual Study Start Date : November 6, 2017
Estimated Primary Completion Date : July 30, 2019
Estimated Study Completion Date : July 30, 2019


Arm Intervention/treatment
Excel V™ Laser With Green Genesis
Treatment with Excel V™ Laser With Green Genesis and Micro-Lens Array (MLA)Attachment for skin quality in desired area
Device: Excel V™ Laser With Green Genesis
Subject(s) will receive 3 to 5 treatments with a Cutera Excel V™ Laser




Primary Outcome Measures :
  1. Photo Assessment of Improvement #1 [ Time Frame: Baseline and 12 weeks post final treatment ]
    Correct photo identification measuring improvement, comparing Baseline photos to 12 weeks post final laser treatment photos, as assessed by three blinded assessors in at least 75% of the subjects.

  2. Assessment of Improvement #2 [ Time Frame: Baseline and 12 weeks post-final treatment ]
    The improvement after treatment from Baseline of ≥1 on the Global Aesthetic Improvement Scale (GAIS), as assessed by three blinded assessors in at least 75% of subjects. GAIS:+4=Very Significant Improvement (≥75%),+3=Significant Improvement(50-74%), +2=Moderate Improvement(25 - 49%), +1=Mild Improvement(5-24%), and 0=No Change(< 5%)


Secondary Outcome Measures :
  1. Measurement #1 of device Adverse Effects (AE) [ Time Frame: through study completion, an average of 1 year ]
    Safety of the Cutera excel V laser with Green Genesis and Micro-Lens Array (MLA) Attachment as assessed by frequency and severity (0=none, 1=mild, 2=moderate, or 3=severe) of device related adverse events as reported up to the 12 week follow-up visit.

  2. Measurement #2 of device Adverse Effects (AE) [ Time Frame: through study completion, an average of 1 year ]
    Safety of the Cutera excel V laser with Micro-Lens Array attachment as assessed by frequency and severity (0=none, 1=mild, 2=moderate or 3=severe) of device adverse events as reported up to the 12 week follow-up visit.

  3. Measurement #3 of skin quality [ Time Frame: 2 to 4 weeks after third treatment and12 weeks post-final treatment ]
    Efficacy of the Cutera excel V laser with Green Genesis to diffuse facial redness and/or improve dyschromia (pigment) as compared to the Standard-of-Care (SOC) procedure using Excel V, as assessed by the study investigator at 2-4 weeks after the 3rd laser treatment visit and at the 12 week follow-up visit, using Skin Quality Rating Scale (1-10): for Radiance, Smoothness, Pigmentation, Erythema and Pore size.

  4. Measurement #4 of wrinkles [ Time Frame: 2 to 4 weeks after third treatment and12 weeks post-final treatment ]
    Efficacy of the Cutera excel V laser with the Micro-Lens Array to treat fine lines and skin texture, as compared to the Standard-of-Care (SOC) procedure using Excel V, as assessed by the study investigator at 2-4 weeks after the 3rd laser treatment visit and at the 12 week follow-up visit using the Fitzpatrick Wrinkle Classification System (FWCS): (1-3=fine wrinkles, 4-6=moderate depth & moderate number of lines, and 7-9=severe depth & numerous lines)

  5. Measurement #4 of acne scarring [ Time Frame: 2 to 4 weeks after third treatment and12 weeks post-final treatment ]
    Efficacy of the Cutera excel V laser with the Micro-Lens Array to improve acne scar severity as compared to the Standard-of-Care (SOC) procedure using Excel V, as assessed by the study investigator at 2-4 weeks after the 3rd laser treatment visit and at the 12 week follow-up visit, using Acne Scar Assessment Scale (ASAS): (+1=clear, +2=very mild, +3=mild, +4=moderate, and 5=severe)



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  1. Subject must be able to read, understand and sign the Informed Consent Form.
  2. Female or Male, 18 to 65 years of age (inclusive).
  3. Fitzpatrick Skin Type I - VI (Appendix 4).
  4. Must be willing to have Cutera excel V laser treatments with MLA and/or Green Genesis (532 nm) and able to adhere to the treatments, follow-up visit schedule, and post-treatment care instructions.
  5. Willing to have very limited sun exposure and use sunscreen on the treatment area every day for the duration of the study, including the follow-up period.
  6. Willing to have digital photographs taken of the treatment area and agree to use of photographs for presentation (educational and/or marketing), publications, and any additional marketing purposes.
  7. Agree to not undergo any other cosmetic procedure(s) or treatment(s) on the face during the study and has no intention of having such procedures performed during the course of the study.
  8. For female subjects: not pregnant or lactating and is either post-menopausal, surgically sterilized, or using a medically acceptable form of birth control at least 3 months prior to enrollment and during the entire course of the study.

Exclusion Criteria:

  1. Participation in a clinical trial of another drug, or device administered to the treatment area, within 3 months prior to enrollment or during the study.
  2. Any type of prior cosmetic treatment to the target area within 3 months of study participation, such as laser procedures, facial fillers, toxins and those used for general aesthetic correction.
  3. Use of prescription topicals in the treatment area within one month prior to treatment or use of topical agents one week prior to treatment that may cause facial sensitivity.
  4. Suffering from significant skin conditions in the treated areas or inflammatory skin conditions, including but not limited to, open lacerations or abrasions, hidradenitis, rash, infection , or dermatitis of the treatment area prior to treatment (duration of resolution as per the Investigator's discretion).
  5. Pregnant and/or breastfeeding, or planning to become pregnant.
  6. Significant concurrent illness, such as diabetes mellitus, immunosuppression/immune deficiency disorders (including HIV infection or AIDS) or using immunosuppressive medication.
  7. Hypersensitivity to light exposure.
  8. Any use of medication that is known to increase sensitivity to light according to the Investigator's discretion.
  9. History of keloid scarring, hypertrophic scarring or abnormal wound healing or prone to bruising.
  10. Has a history of squamous cell carcinoma or melanoma in the treatment area.
  11. History of epidermal or dermal disorders (particularly if involving collagen or microvascularity), including collagen vascular disease or vasculitic disorders.
  12. A history or active skin condition that in the opinion of the Investigator may interfere/confound with the treatment.
  13. History of connective tissue disease, such as systemic lupus erythematosus or scleroderma.
  14. History of disease stimulated by heat, such as recurrent herpes simplex and/or herpes zoster (shingles) in the treatment area, unless treatment is conducted following a prophylactic regimen.
  15. History of pigmentary disorders, particularly tendency for hyper- or hypo- pigmentation, or any that are considered not acceptable by the study investigator.
  16. Has used oral isotretinoin (Accutane or therapeutic vitamin A supplements of equal to, or greater than 10,000 units per day) within 12 months of initial treatment or plans on using during the course of the study (note: skin must regain its normal degree of moisture prior to treatment, e.g. lack of noticeable skin flaking and peeling).
  17. Excessively tanned or active sun tan in facial area to be treated, or unable/unlikely to refrain from tanning during the study.
  18. Excessive facial hair in the area to be treated (beards, sideburns, and/or moustache,) that would interfere with diagnosis, assessment, and treatment.
  19. As per the Investigator's discretion, any physical or mental condition which might make it unsafe for the subject to participate in this study, including excessive alcohol or drug abuses, or a condition that would compromise the subject's ability to comply with the study requirements.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03424304


Locations
Layout table for location information
United States, California
Cutera Research Center
Brisbane, California, United States, 94005
Sponsors and Collaborators
Cutera Inc.
Investigators
Layout table for investigator information
Principal Investigator: Stephen Ronan, MD Cutera Research Center

Layout table for additonal information
Responsible Party: Cutera Inc.
ClinicalTrials.gov Identifier: NCT03424304     History of Changes
Other Study ID Numbers: C-17-EV12
First Posted: February 7, 2018    Key Record Dates
Last Update Posted: March 14, 2018
Last Verified: December 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: Yes
Device Product Not Approved or Cleared by U.S. FDA: Yes
Pediatric Postmarket Surveillance of a Device Product: No
Product Manufactured in and Exported from the U.S.: No

Additional relevant MeSH terms:
Layout table for MeSH terms
Rosacea
Skin Diseases
Chlorhexidine
Chlorhexidine gluconate
Triamcinolone
Anti-Infective Agents, Local
Anti-Infective Agents
Disinfectants
Dermatologic Agents
Anti-Inflammatory Agents
Glucocorticoids
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs